GLP-1 & Incretin Science

Disclosure Is Not Disqualification

UKPWritten and published by UK Peptides4 min readUpdated 3 cited sources

The short answer

A conflict of interest statement tells you who paid, who was employed, and who held stock. It does not tell you whether a paper is right. The useful move is to identify the judgement calls only the authors could make and weigh those against the declared interest.

Key facts

Worked example
Ciudin et al., Adv Ther 2026 (PMID 41820778)
Funding statement
Sponsored by Eli Lilly, which also funded rapid service and open access fees
Employee authors
5 of 9 declared as employees and shareholders of Eli Lilly
Contracted authors
3 employed by Costello Medical, paid by Lilly for analytical services
Independent author
1, declaring honoraria from four companies including Lilly
Medical writing
Costello Medical, funded by Eli Lilly
Drug favoured by result
Tirzepatide, marketed by Eli Lilly
Data availability
From the corresponding author on reasonable request

What the statement actually contains

Take the 2026 Bayesian network meta-analysis of tirzepatide, semaglutide and liraglutide as a worked example, because its declarations are unusually complete. The funding statement says the study was sponsored by Eli Lilly and that Lilly also paid the journal's rapid service and open access fees. The conflict of interest section names five authors as employees and shareholders of Eli Lilly and Company, three as employees of Costello Medical which received payment from Lilly for analytical services for this study, and one (the lead author, a clinician) as receiving honoraria from AstraZeneca, Boehringer Ingelheim, Lilly and Novo Nordisk. A separate acknowledgement names the medical writing and statistical support, also at Costello Medical, also funded by Lilly. The result favours tirzepatide, which is Lilly's product.

Why complete disclosure is a good sign, not a bad one

It is tempting to treat a long conflicts section as a warning. It is closer to the opposite. Everything above is knowable only because the paper states it, in a standard place, in plain language. The papers that deserve concern are the ones where the funding is vague, the writing assistance is unacknowledged, or the analytical contractor is invisible. A disclosure this granular gives the reader what they need to scrutinise the work, and the reader's job is to use it rather than to treat it as a verdict.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What sponsorship does and does not predict

There is a substantial literature showing that industry-sponsored studies more often report conclusions favourable to the sponsor than independently funded studies of the same questions. That is an association across bodies of literature, and it is a legitimate reason to apply extra scrutiny to any single sponsored paper. It is not a finding about any individual study, and treating it as one is a category error: it would require discarding most of the evidence base for most licensed medicines, since pivotal trials are almost universally sponsor-funded.

Locate the discretionary decisions

The more useful question is where a sponsor's preference could have entered, rather than whether the work was sponsored. In a randomised trial, most of the structure is fixed in a protocol and registered in advance, which constrains discretion considerably. In a meta-analysis the discretion is much larger and sits in the inclusion criteria: this analysis identified 42 randomised trials and included six. Which six is the single most consequential decision in the paper, it was made by the analysts, and it is where scrutiny belongs. The stated reason, a heterogeneity assessment requiring comparable design, population, background therapy and estimands, is a legitimate one, and the six trials are named so the reasoning can be checked against the supplementary material.

Then look for the external check

The strongest response to a conflict of interest is corroboration. This analysis estimated tirzepatide 15 mg at 6.26 percentage points better than semaglutide 2.4 mg on weight. SURMOUNT-5, a head-to-head trial the authors state was published after their analysis was conducted and which they excluded, found 6.5 percentage points. SURMOUNT-5 was itself Lilly-funded, so that is not fully independent corroboration. It is, however, a prospectively randomised, registered comparison rather than an analyst's reconstruction, and the agreement is close. Independent real-world cohorts point the same direction with smaller effects. Convergence from designs with different biases counts for more than any declaration.

A short procedure

Read the funding statement and the conflicts section before the results, so the results do not colour how you read them. Identify who employed the analysts as distinct from who employed the clinicians. Find the decisions that were discretionary rather than protocol-bound. Check whether those decisions are documented well enough to audit. Then look for whether anything with a different set of biases agrees. If the answer to the last two is yes, the declared interest is information you hold rather than a reason to discard the work.

Frequently asked questions

Should I ignore industry-funded research?

No, and it is not practical to. Almost all pivotal drug trials are sponsor-funded, because almost nobody else funds them. The realistic approach is to read them with their sponsorship known and to weight corroboration from differently biased sources heavily.

What is a medical communications agency doing on an author list?

Providing statistical analysis, writing and editorial support under contract, which is common and legitimate when disclosed. The relevant question is whether their role is stated (here it is, including which individuals did the statistical work and who paid for it) rather than whether they were involved.

Does an author holding shares matter more than receiving honoraria?

They are different kinds of interest. Equity ties personal wealth to a company's performance in a continuing way; an honorarium is a discrete payment. Both are disclosed for a reason and neither is automatically decisive.

Where do I find these statements?

In the paper itself, usually under Declarations, Funding, or Conflict of Interest near the end, and in the full text rather than the abstract. Abstract-only reading is how most conflicts go unnoticed, because the abstract never carries them.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.